Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Thanks for the links regarding Anavex; chromatin.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
falconer66a Member Profile
 
Followed By 101
Posts 1,821
Boards Moderated 0
Alias Born 01/29/04
160x600 placeholder
Anavex Life Sciences EPS beats by $0.03 Seeking Alpha - 5/13/2021 7:11:29 AM
Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook GlobeNewswire Inc. - 5/13/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit GlobeNewswire Inc. - 5/7/2021 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021 GlobeNewswire Inc. - 5/6/2021 7:00:00 AM
Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development GlobeNewswire Inc. - 5/5/2021 7:00:00 AM
Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference GlobeNewswire Inc. - 4/26/2021 7:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/12/2021 4:06:51 PM
Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials o... GlobeNewswire Inc. - 4/12/2021 7:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 4/9/2021 5:07:26 PM
Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire Inc. - 4/8/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021 GlobeNewswire Inc. - 4/7/2021 7:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/1/2021 4:14:18 PM
DSMB recommends continuation of Anavex Life's late-stage Alzheimer’s study Seeking Alpha - 3/31/2021 7:14:03 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of... GlobeNewswire Inc. - 3/31/2021 7:00:00 AM
Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical T... GlobeNewswire Inc. - 3/16/2021 7:00:00 AM
Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire Inc. - 3/4/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease ... GlobeNewswire Inc. - 2/22/2021 7:00:00 AM
Nextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to $50-60 Million, $8.60 Valuation InvestorsHub NewsWire - 2/22/2021 6:18:20 AM
Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit GlobeNewswire Inc. - 2/19/2021 7:00:00 AM
Anavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 GlobeNewswire Inc. - 2/18/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 4:07:35 PM
Nextech AR (OTCQB: NEXCF) 2021 Guidance $50-60 Million Closes 2020 with $20 million. InvestorsHub NewsWire - 2/12/2021 6:26:34 AM
Anavex Life Sciences EPS in-line Seeking Alpha - 2/11/2021 7:22:45 AM
Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook GlobeNewswire Inc. - 2/11/2021 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2... GlobeNewswire Inc. - 2/8/2021 7:00:00 AM
falconer66a   Monday, 02/15/21 04:08:20 PM
Re: sokol post# 299108
Post # of 310400 
Thanks for the links regarding Anavex; chromatin.

This abstract excerpt from your link provides the appropriate focus:
Quote:
Epigenetic mechanisms are fundamental key features of developing cells connecting developmental regulatory factors to chromatin modification.


The real story, I believe, will not be Anavex's chromatin modulation, per se; rather it will be the suppression of adverse epigenetics. Now, the Anavex epigenetics factor will come into consideration and play.

In classical genetics (which I taught my talented advanced placement biology students, and everyone learned in a biology course), DNA is a sequence of nucleotides, A's and T's, G's and C's. Those precise sequences form the genetic code, which, by translation directs the ribosomes to precisely connect amino acids in strands called peptides. In the endoplasmic reticula the peptides are both connected and precisely folded, producing proteins, most often enzyme proteins that control virtually all of the cell's chemical reactions.

If the peptide/proteins get misfolded, bad chemistry happens. Blarcamesine tends to prevent this.

But often, "epigenetics" are involved, where poorly functioning proteins are formed, because of translation errors involving chromatin malfunctions. New, unintended adverse reactions occur. Many diseases are epigenetic, including many cancers. Keep epigenetic anomalies from developing and the health of an organism is greatly improved.

Let's watch to see how epigenetics, involving chromatin modulation, now enter the Anavex discussions. Really big. A gigantic new medical landscape for the company.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences